HistoRx currently has 10 such partnerships with leading pharmaceutical companies such as Lilly involving therapeutics in multiple stages of development. Researchers at these companies are using AQUA(R) analysis-based assays to identify correlations of biomarker expression with clinical outcomes, including drug dosing effects, therapeutic mechanism of action, drug safety, and therapeutic efficacy.
"We consider this expanded agreement with Lilly, one of the world's leading innovation-driven pharmaceutical companies, to be a tremendous validation of the HistoRx AQUA(R) technology," said Rana K. Gupta, CEO of HistoRx. "By revealing stronger, more reliable statistical correlations linking protein biomarker expression with prediction of patient response to therapy and disease outcome, we expect this ongoing partnership to continue providing a substantial boost to Lilly's drug research and development programs."
About HistoRx (http://www.historx.com)
HistoRx, Inc. is a leader in the emerging field of tissue-based
diagnostic products for targeted patient treatment. The company's products
and services are based on proprietary AQUA(R) technology, the first
platform capable of measuring biomarker concentration with subcellular
resolution in tissue sections in a fully standardized and automated manner.
HistoRx partners with pharmaceutical and biotechnology companies to
generate precise and cost- effective answers about the safety and
effectiveness of targeted therapeutics in development for cancer and other
diseases. These partnerships provide the foundation for HistoRx to develop
companion diagnostic tests that will be co- marketed with partners'
targeted therapeutics. HistoRx also pursues internal programs to develop
proprietary diagnostics that will enable improved treatment decisions in
|SOURCE HistoRx, Inc.|
Copyright©2008 PR Newswire.
All rights reserved